Viking Therapeutics, Inc. (LON: 0VQA)

Viking Therapeutics Statistics

Total Valuation

Viking Therapeutics has a market cap or net worth of GBP 2.94 billion. The enterprise value is 2.19 billion.

Market Cap	2.94B
Enterprise Value	2.19B

Important Dates

The next estimated earnings date is Wednesday, February 5, 2025.

Earnings Date	Feb 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+19.97%
Shares Change (QoQ)	+0.47%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	108.95M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	4.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-29.58
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 36.47, with a Debt / Equity ratio of 0.00.

Current Ratio	36.47
Quick Ratio	36.23
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,395.49

Financial Efficiency

Return on equity (ROE) is -15.50% and return on invested capital (ROIC) is -13.06%.

Return on Equity (ROE)	-15.50%
Return on Assets (ROA)	-12.68%
Return on Invested Capital (ROIC)	-13.06%
Return on Capital Employed (ROCE)	-14.69%
Revenue Per Employee	n/a
Profits Per Employee	-2.39M
Employee Count	27
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +37.28% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+37.28%
50-Day Moving Average	43.15
200-Day Moving Average	57.25
Relative Strength Index (RSI)	29.98
Average Volume (20 Days)	9,008

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.62

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-99.95M
Pretax Income	-73.98M
Net Income	-73.98M
EBITDA	n/a
EBIT	-99.95M
Earnings Per Share (EPS)	-0.70

Balance Sheet

The company has 694.20 million in cash and 921,434 in debt, giving a net cash position of 693.28 million.

Cash & Cash Equivalents	694.20M
Total Debt	921,434
Net Cash	693.28M
Net Cash Per Share	n/a
Equity (Book Value)	680.03M
Book Value Per Share	6.10
Working Capital	679.67M

Cash Flow

Operating Cash Flow	-55.40M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Viking Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.97%
Shareholder Yield	-19.97%
Earnings Yield	-2.52%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a